Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Keiichiro Haga is active.

Publication


Featured researches published by Keiichiro Haga.


Journal of Gastroenterology | 1999

Development of poorly differentiated adenocarcinoma and carcinoid due to long-term Helicobacter pylori colonization in Mongolian gerbils

Fumihiro Hirayama; Shiro Takagi; Eiji Iwao; Yoshito Yokoyama; Keiichiro Haga; Shuichi Hanada

Abstract: A Mongolian gerbil model was used to clarify whether long-term colonization by Helicobacter pylori is an important risk factor for the development of gastric cancer. Fifty-nine gerbils (3 controls and 56 gerbils inoculated with H. pylori) were killed at various times (average, 23 months) more than 12 months after H. pylori inoculation. In the H. pylori-inoculated group, poorly differentiated adenocarcinoma was observed in the pylorus of 1 gerbil, and carcinoid was observed in the fundus of the stomach in 18 gerbils. No lesions were found in the stomachs of the 3 control gerbils. The results imply that long-term colonization by H. pylori is an important risk factor for the development of gastric adenocarcinoma and carcinoid.


Bioorganic & Medicinal Chemistry | 2003

Design and synthesis of orally active benzamide derivatives as potent serotonin 4 receptor agonist

Shuji Sonda; Toshio Kawahara; Takahiro Murozono; Noriko Sato; Kiyoshi Asano; Keiichiro Haga

A series of 4-amino-5-chloro-2-methoxy-N-(piperidin-4-ylmethyl)benzamide derivatives bearing an aralkylamino, alkylamino, benzoyl or phenylsulfonyl group at its side chain part at the 1-position on the piperidine ring was synthesized. They were evaluated for serotonin 4 (5-HT(4)) receptor agonist activity by testing their ability to contract the isolated guinea-pig ascending colon. 4-Amino-5-chloro-2-methoxy-N-[1-[5-(1-methylindol-3-ylcarbonylamino)pentyl]piperidin-4-ylmethyl]benzamide (1a, Y-34959) and its related compounds possessed favorable pharmacological profiles for gastrointestinal motility. Unfortunately, the compound 1a showed low bioavailability when given orally presumably due to its poor intestinal absorption rate. Replacement of the 1-methylindol-3-yl carbonylamino moiety of 1a with an aralkylamino (or alkylamino) group did not improve the intestinal absorption rate. Replacement of the 1-methylindol-3-ylcarbonylamino moiety with a benzoyl or phenylsulfonyl group increased the intestinal absorption rate compared with 1a. These compounds revealed good pharmacological profiles for gastrointestinal motility and were superior to 1a in oral bioavailability.


Journal of Gastroenterology | 2002

Long-term effects of Helicobacter pylori eradication in Mongolian gerbils

Fumihiro Hirayama; Shiro Takagi; Yoshito Yokoyama; Katsuhiro Yamamoto; Eiji Iwao; Keiichiro Haga

Background: In this study, to clarify whether Helicobacter pylori eradication alters the course of the development of gastric mucosal changes in the stomach, we examined the long-term effects of H. pylori eradication on H. pylori-inoculated gerbils. Methods: A total of 40 H. pylori-inoculated gerbils were randomized and subjected, at 22 months after inoculation, to eradication treatment with dual therapy of omeprazole plus clarithromycin, or with therapy with a novel quinolone compound, Y-34867, alone. The animals were killed at the start of administration (control group) or at 8 months after the completion of therapy (vehicle or eradication-treatment groups). Results: Severe histopathological changes in the gastric mucosa were observed in all H. pylori-inoculated gerbils at the start of administration. At 8 months after completion of therapy, the frequency of gastritis, erosion, intestinal metaplasia, and gastric carcinoid in the eradication therapy groups was markedly reduced compared with that in the control and vehicle groups. Values for anti-H. pylori IgG titer, bacterial counts, and gastrin also decreased significantly. Conclusions: These results suggest that H. pylori eradication may have had a therapeutic effect not only on gastritis, erosion, and gastric ulcer but also on glandular atrophy, intestinal metaplasia, and gastric carcinoid.


Japanese Journal of Pharmacology | 1992

Antagonistic Activity of Y-25130 on 5-HT3 Receptors

Noriko Sato; Masamitsu Sakamori; Keiichiro Haga; Shuzo Takehara; Michihide Setoguchi


Archive | 1997

Benzoic acid compounds and use thereof as medicaments

Takeshi Kawakita; Takanobu Kuroita; Takahiro Murozono; Hidetoshi Hakira; Keiichiro Haga; Katsuhiko Ito; Shuji Sonda; Toshio Kawahara; Kiyoshi Asano


European Journal of Medicinal Chemistry | 1999

Synthesis and pharmacological evaluation of carboxamide derivatives as selective serotoninergic 5-HT4 receptor agonists

Katsuhiko Itoh; Koji Kanzaki; Tsuguo Ikebe; Takanobu Kuroita; Hideo Tomozane; Shuji Sonda; Noriko Sato; Keiichiro Haga; Takeshi Kawakita


Archive | 1994

Pyridine compound and pharmaceutical compostions

Takeshi Kawakita; Mitsuharu Sano; Yuko Yutoku; Yoshifumi Ikeda; Keiichiro Haga


Japanese Journal of Pharmacology | 1993

The Effects of Orally Administered Y-25130, a Selective Serotonin3-Receptor Antagonist, on Chemotherapeutic Agent-Induced Emesis.

Keiichiro Haga; Kenichi Inaba; Hidenori Shoji; Yasuto Morimoto; Takemi Fukuda; Michihide Setoguchi


Archive | 1991

Use of pyridine compound as selective drug and novel pyridine compound.

Takeshi Kawakita; Mitsuharu Sano; Yoshifumi Ikeda; Eiji Iwao; Keiichiro Haga


Journal of Infection and Chemotherapy | 2004

Potent antibacterial activity of Y-754, a novel benzimidazole compound with selective action against Helicobacter pylori

Eiji Iwao; Katsuhiro Yamamoto; Yoshito Yokoyama; Fumihiro Hirayama; Keiichiro Haga

Collaboration


Dive into the Keiichiro Haga's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takanobu Kuroita

Takeda Pharmaceutical Company

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge